Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 19 on this page, newest registry updates first. Search checked 2026-11-08 18:40 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2UnknownINTERVENTIONAL

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

ClinicalTrials.gov · NCT01731925 · Registry updated: 2017-01-31

Condition / research focus: Carcinoid Tumors
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Countries with listed sites: Belgium · France
Registry dates and results: Start: 2013-01-07. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug)
Placebo (for sunitinib) (drug)
Sunitinib (drug)

Where the study takes place — 20 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Cliniques Universitaires Saint Luc
Brussels, Belgium
Site recruitment: Not reported
Institut Jules Bordet
Brussels, Belgium
Site recruitment: Not reported
ULB Erasme
Brussels, Belgium
Site recruitment: Not reported
UZ Antwerpen
Edegem, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Belgium
Site recruitment: Not reported
UZ Leuven
Leuven, Belgium
Site recruitment: Not reported
Hôpital Saint André
Bordeaux, France
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
Hôpital Henri Mondor
Créteil, France
Site recruitment: Not reported
Hopital Saint Vincent de Paul
Lille, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
CHU La Timone
Marseille, France
Site recruitment: Not reported
Hôpital St Antoine
Paris, France
Site recruitment: Not reported
CHU Cochin
Paris, France
Site recruitment: Not reported
Hôpital Pitié Salpêtrière
Paris, France
Site recruitment: Not reported
Institut Mutualiste Montsouris
Paris, France
Site recruitment: Not reported
CHU Robert Debré
Reims, France
Site recruitment: Not reported
CHU Pontchaillou
Rennes, France
Site recruitment: Not reported
CHU Rouen
Rouen, France
Site recruitment: Not reported
CHRU Trousseau
Tours, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

ClinicalTrials.gov · NCT01372007 · Registry updated: 2016-10-07

Condition / research focus: Rectal Carcinoma
Sponsor: University Hospital, Ghent
Countries with listed sites: Belgium
Registry dates and results: Start: 2011-07. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel 120mg (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Universital Hospital Ghent
Ghent, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Pasireotide LAR and Pegvisomant Study in Acromegaly

ClinicalTrials.gov · NCT02668172 · Registry updated: 2016-08-03

Condition / research focus: Acromegaly
Sponsor: Erasmus Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2015-08. Completion: 2017-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pasireotide LAR 60 mg (drug) — also listed as: Signifor, SOM230
Pegvisomant (drug) — also listed as: Somavert

Where the study takes place — 1 listed sites

Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

ClinicalTrials.gov · NCT01076803 · Registry updated: 2014-12-05

Condition / research focus: Malignant Intestinal Obstruction
Sponsor: University Hospital, Ghent
Countries with listed sites: Belgium
Registry dates and results: Start: 2009-10. Completion: 2013-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (acetate) (drug)

Where the study takes place — 1 listed sites

University Hospital Ghent
Ghent, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

ClinicalTrials.gov · NCT01354405 · Registry updated: 2014-07-09

Condition / research focus: Polycystic Liver Disease
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2011-05. Completion: 2014-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 1 listed sites

Radboud University Hospital
Nijmegen, Gelderland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

ClinicalTrials.gov · NCT01315795 · Registry updated: 2014-07-08

Condition / research focus: Polycystic Liver Disease
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium
Registry dates and results: Start: 2011-03. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel 90 mg and 120 mg (drug)

Where the study takes place — 1 listed sites

UZ Leuven, Gasthuisberg
Leuven, Provincie Vlaams-Brabant, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

ClinicalTrials.gov · NCT02054637 · Registry updated: 2014-02-04

Condition / research focus: Acid Reflux Esophagitis; Non-acid Reflux Esophagitis
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-04. Completion: 2016-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 1 listed sites

University Hospital of Brussels
Jette, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

ClinicalTrials.gov · NCT00652379 · Registry updated: 2012-01-26

Condition / research focus: Acromegaly; Insulin Resistance; Impaired Glucose Tolerance
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-06. Completion: 2011-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pegvisomant (drug) — also listed as: Somavert
Somatostatin analog (lanreotide or octreotide) (drug)

Where the study takes place — 1 listed sites

Department of Endocrinology, Aarhus University Hospital
Aarhus C, Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

ClinicalTrials.gov · NCT00630695 · Registry updated: 2012-01-16

Condition / research focus: Lymphocele
Sponsor: University Hospital, Limoges
Countries with listed sites: France
Registry dates and results: Start: 2008-03. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide LP 90 (drug)
Placebo lanreotide (drug)

Where the study takes place — 1 listed sites

Hôpital Mère Enfant- CHU de Limoges
Limoges, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

ClinicalTrials.gov · NCT00993356 · Registry updated: 2009-10-12

Condition / research focus: Acromegaly
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2004-01. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Preoperative lanreotide treatment (drug)
Transsphenoidal surgery (procedure)

Where the study takes place — 1 listed sites

Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

ClinicalTrials.gov · NCT00495846 · Registry updated: 2009-08-17

Condition / research focus: Advanced Hepatocellular Carcinoma
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 2007-04. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide-LAR, Lanreotide Autogel (drug) — also listed as: Sandostatin-LAR, Ipstyl 120 mg, Somatuline Depot
Locoregional treatments (other)

Where the study takes place — 1 listed sites

D. Cotugno Hospital
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Lanreotide Levels in Acromegaly

ClinicalTrials.gov · NCT00916916 · Registry updated: 2009-06-10

Condition / research focus: Acromegaly
Sponsor: Cedars-Sinai Medical Center
Countries with listed sites: United States
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Blood draw (other)

Where the study takes place — 1 listed sites

Cedars-Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Lanreotide as Treatment of Polycystic Livers

ClinicalTrials.gov · NCT00565097 · Registry updated: 2009-02-17

Condition / research focus: Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney, Autosomal Dominant
Sponsor: Radboud University Medical Center
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2007-10. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
Lanreotide (drug)

Where the study takes place — 2 listed sites

University Hospital Gasthuisberg
Leuven, Belgium
Site recruitment: Not reported
Radboud University Medical Center
Nijmegen, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

Open-Label Extension of LOCKCYST Trial

ClinicalTrials.gov · NCT00771888 · Registry updated: 2008-11-13

Condition / research focus: Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney; Autosomal Dominant
Sponsor: Radboud University Medical Center
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2008-04. Completion: 2009-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (drug)

Where the study takes place — 2 listed sites

University Hospital Gasthuisberg, University of Leuven
Leuven, Belgium
Site recruitment: Not reported
Radboud University Nijmegen Medical Center
Nijmegen, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly

ClinicalTrials.gov · NCT00703079 · Registry updated: 2008-06-23

Condition / research focus: Acromegaly
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 1997-01. Completion: 2008-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide-LAR or lanreotide (drug) — also listed as: Sandostatin-LAR (Novartis), Ipstyl (Ipsen)
Transsphenoidal adenomectomy (procedure)

Where the study takes place — 1 listed sites

Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

ClinicalTrials.gov · NCT00627796 · Registry updated: 2008-03-03

Condition / research focus: Acromegaly
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 2003-01. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide-Autogel 120 mg (drug) — also listed as: Ipstyl

Where the study takes place — 1 listed sites

Annamaria Colao
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Cardiovascular Outcome After Surgery or Somatostatin Analogues

ClinicalTrials.gov · NCT00615004 · Registry updated: 2008-02-14

Condition / research focus: Acromegaly
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 1997-01. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
Naples, Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Treatment of the Dumping Syndrome With Lanreotide Autogel®

ClinicalTrials.gov · NCT00543179 · Registry updated: 2007-10-12

Condition / research focus: Dumping Syndrome
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2007-10. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Somatuline (Lanreotide Autogel®) (drug)

Where the study takes place — 1 listed sites

UMC St. Radboud Medical Center
Nijmegen, Gelderland, Netherlands
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

ClinicalTrials.gov · NCT00145405 · Registry updated: 2006-09-08

Condition / research focus: Acromegaly
Sponsor: Odense University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2002-09. Completion: 2004-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel and Octreotide LAR (drug)

Where the study takes place — 1 listed sites

Department of Endocrinology, Odense University Hospital
Odense, Funen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 19 on this page, newest registry updates first. Search checked 2026-11-08 18:40 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2UnknownINTERVENTIONAL

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

ClinicalTrials.gov · NCT01731925 · Registry updated: 2017-01-31

Condition / research focus: Carcinoid Tumors
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Countries with listed sites: Belgium · France
Registry dates and results: Start: 2013-01-07. Completion: 2017-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug)
Placebo (for sunitinib) (drug)
Sunitinib (drug)

Where the study takes place — 20 listed sites

Cliniques Universitaires Saint Luc
Brussels, Belgium
Site recruitment: Not reported
Institut Jules Bordet
Brussels, Belgium
Site recruitment: Not reported
ULB Erasme
Brussels, Belgium
Site recruitment: Not reported
UZ Antwerpen
Edegem, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Belgium
Site recruitment: Not reported
UZ Leuven
Leuven, Belgium
Site recruitment: Not reported
Hôpital Saint André
Bordeaux, France
Site recruitment: Not reported
Hôpital Beaujon
Clichy, France
Site recruitment: Not reported
Hôpital Henri Mondor
Créteil, France
Site recruitment: Not reported
Hopital Saint Vincent de Paul
Lille, France
Site recruitment: Not reported
Hôpital Edouard Herriot
Lyon, France
Site recruitment: Not reported
CHU La Timone
Marseille, France
Site recruitment: Not reported
Hôpital St Antoine
Paris, France
Site recruitment: Not reported
CHU Cochin
Paris, France
Site recruitment: Not reported
Hôpital Pitié Salpêtrière
Paris, France
Site recruitment: Not reported
Institut Mutualiste Montsouris
Paris, France
Site recruitment: Not reported
CHU Robert Debré
Reims, France
Site recruitment: Not reported
CHU Pontchaillou
Rennes, France
Site recruitment: Not reported
CHU Rouen
Rouen, France
Site recruitment: Not reported
CHRU Trousseau
Tours, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

ClinicalTrials.gov · NCT01372007 · Registry updated: 2016-10-07

Condition / research focus: Rectal Carcinoma
Sponsor: University Hospital, Ghent
Countries with listed sites: Belgium
Registry dates and results: Start: 2011-07. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel 120mg (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Universital Hospital Ghent
Ghent, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Pasireotide LAR and Pegvisomant Study in Acromegaly

ClinicalTrials.gov · NCT02668172 · Registry updated: 2016-08-03

Condition / research focus: Acromegaly
Sponsor: Erasmus Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2015-08. Completion: 2017-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pasireotide LAR 60 mg (drug) — also listed as: Signifor, SOM230
Pegvisomant (drug) — also listed as: Somavert

Where the study takes place — 1 listed sites

Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

ClinicalTrials.gov · NCT01076803 · Registry updated: 2014-12-05

Condition / research focus: Malignant Intestinal Obstruction
Sponsor: University Hospital, Ghent
Countries with listed sites: Belgium
Registry dates and results: Start: 2009-10. Completion: 2013-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (acetate) (drug)

Where the study takes place — 1 listed sites

University Hospital Ghent
Ghent, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

ClinicalTrials.gov · NCT01354405 · Registry updated: 2014-07-09

Condition / research focus: Polycystic Liver Disease
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2011-05. Completion: 2014-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 1 listed sites

Radboud University Hospital
Nijmegen, Gelderland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

ClinicalTrials.gov · NCT01315795 · Registry updated: 2014-07-08

Condition / research focus: Polycystic Liver Disease
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium
Registry dates and results: Start: 2011-03. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel 90 mg and 120 mg (drug)

Where the study takes place — 1 listed sites

UZ Leuven, Gasthuisberg
Leuven, Provincie Vlaams-Brabant, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

ClinicalTrials.gov · NCT02054637 · Registry updated: 2014-02-04

Condition / research focus: Acid Reflux Esophagitis; Non-acid Reflux Esophagitis
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-04. Completion: 2016-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide (drug) — also listed as: Somatuline

Where the study takes place — 1 listed sites

University Hospital of Brussels
Jette, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

ClinicalTrials.gov · NCT00652379 · Registry updated: 2012-01-26

Condition / research focus: Acromegaly; Insulin Resistance; Impaired Glucose Tolerance
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-06. Completion: 2011-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pegvisomant (drug) — also listed as: Somavert
Somatostatin analog (lanreotide or octreotide) (drug)

Where the study takes place — 1 listed sites

Department of Endocrinology, Aarhus University Hospital
Aarhus C, Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

ClinicalTrials.gov · NCT00630695 · Registry updated: 2012-01-16

Condition / research focus: Lymphocele
Sponsor: University Hospital, Limoges
Countries with listed sites: France
Registry dates and results: Start: 2008-03. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide LP 90 (drug)
Placebo lanreotide (drug)

Where the study takes place — 1 listed sites

Hôpital Mère Enfant- CHU de Limoges
Limoges, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

ClinicalTrials.gov · NCT00993356 · Registry updated: 2009-10-12

Condition / research focus: Acromegaly
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2004-01. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Preoperative lanreotide treatment (drug)
Transsphenoidal surgery (procedure)

Where the study takes place — 1 listed sites

Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

ClinicalTrials.gov · NCT00495846 · Registry updated: 2009-08-17

Condition / research focus: Advanced Hepatocellular Carcinoma
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 2007-04. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide-LAR, Lanreotide Autogel (drug) — also listed as: Sandostatin-LAR, Ipstyl 120 mg, Somatuline Depot
Locoregional treatments (other)

Where the study takes place — 1 listed sites

D. Cotugno Hospital
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Lanreotide Levels in Acromegaly

ClinicalTrials.gov · NCT00916916 · Registry updated: 2009-06-10

Condition / research focus: Acromegaly
Sponsor: Cedars-Sinai Medical Center
Countries with listed sites: United States
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Blood draw (other)

Where the study takes place — 1 listed sites

Cedars-Sinai Medical Center
Los Angeles, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Lanreotide as Treatment of Polycystic Livers

ClinicalTrials.gov · NCT00565097 · Registry updated: 2009-02-17

Condition / research focus: Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney, Autosomal Dominant
Sponsor: Radboud University Medical Center
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2007-10. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
Lanreotide (drug)

Where the study takes place — 2 listed sites

University Hospital Gasthuisberg
Leuven, Belgium
Site recruitment: Not reported
Radboud University Medical Center
Nijmegen, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

Open-Label Extension of LOCKCYST Trial

ClinicalTrials.gov · NCT00771888 · Registry updated: 2008-11-13

Condition / research focus: Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney; Autosomal Dominant
Sponsor: Radboud University Medical Center
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2008-04. Completion: 2009-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

lanreotide (drug)

Where the study takes place — 2 listed sites

University Hospital Gasthuisberg, University of Leuven
Leuven, Belgium
Site recruitment: Not reported
Radboud University Nijmegen Medical Center
Nijmegen, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly

ClinicalTrials.gov · NCT00703079 · Registry updated: 2008-06-23

Condition / research focus: Acromegaly
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 1997-01. Completion: 2008-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Octreotide-LAR or lanreotide (drug) — also listed as: Sandostatin-LAR (Novartis), Ipstyl (Ipsen)
Transsphenoidal adenomectomy (procedure)

Where the study takes place — 1 listed sites

Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

ClinicalTrials.gov · NCT00627796 · Registry updated: 2008-03-03

Condition / research focus: Acromegaly
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 2003-01. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide-Autogel 120 mg (drug) — also listed as: Ipstyl

Where the study takes place — 1 listed sites

Annamaria Colao
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Cardiovascular Outcome After Surgery or Somatostatin Analogues

ClinicalTrials.gov · NCT00615004 · Registry updated: 2008-02-14

Condition / research focus: Acromegaly
Sponsor: Federico II University
Countries with listed sites: Italy
Registry dates and results: Start: 1997-01. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
Naples, Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Treatment of the Dumping Syndrome With Lanreotide Autogel®

ClinicalTrials.gov · NCT00543179 · Registry updated: 2007-10-12

Condition / research focus: Dumping Syndrome
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2007-10. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Somatuline (Lanreotide Autogel®) (drug)

Where the study takes place — 1 listed sites

UMC St. Radboud Medical Center
Nijmegen, Gelderland, Netherlands
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

ClinicalTrials.gov · NCT00145405 · Registry updated: 2006-09-08

Condition / research focus: Acromegaly
Sponsor: Odense University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2002-09. Completion: 2004-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lanreotide Autogel and Octreotide LAR (drug)

Where the study takes place — 1 listed sites

Department of Endocrinology, Odense University Hospital
Odense, Funen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →